• Ramon Colomer, Antonio Llombart-Cussac, Belen Lloveras, Manuel Ramos, Jose I Mayordomo, Roberto Fernández, Ignasi Tusquets, Miguel Gil, Agustí Barnadas, Manuel Constenla, Montserrat Gilabert, and Emilio Alba.
• M. D. Anderson Cancer Center Spain, Madrid, Spain. rcolomer@seom.org
• Cancer. 2007 Nov 15; 110 (10): 2178-85.

BackgroundIn this specifically designed, prospective study, the authors addressed the predictive value of circulating levels of the extracellular domain (ECD) of HER2 in patients with metastatic breast cancer who were treated with letrozole.MethodsTwo hundred twenty-six patients with hormone receptor-positive, metastatic breast cancer received letrozole (2.5 mg daily) until they developed either disease progression or unacceptable toxicity. Efficacy was measured primarily as the time to progression (TTP) and, secondarily, as the objective response rate (ORR) and overall survival. HER2 ECD levels were determined by using a sandwich enzyme HER2/neu immunoassay before letrozole treatment was initiated. Positive HER2 ECD status was correlated with treatment efficacy.ResultsForty-two patients (19%) had elevated HER2 ECD levels, which were associated with primary tumor HER2 expression (P < .001) but not with age, performance status, location, or number of metastatic sites. The median TTP was significantly shorter among patients who had elevated HER2 ECD compared with the median TTP among patients who had normal levels (4 months vs 14 months; P = .0004), and the ORR was lower in the group with elevated HER2 ECD levels (14% vs 30%; P < .036). Overall survival was significantly shorter among patients with elevated serum HER-2 ECD (P < .0005).ConclusionsElevated HER2 ECD concentrations predicted poorer outcomes in postmenopausal women with metastatic hormone receptor-positive breast cancer who were treated with aromatase inhibitors like letrozole.(c) 2007 American Cancer Society.

23 keywords...

hide…